Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:
“What is interesting in ASCO GU25.
1 – Surgery vs RT for High Risk Prostate cancer. -IPD Data from 2 RCT
2 – OS for checkmate274
3 – PCR analysis for Nigeria trial
4 – Final OS for Talapro-2 trial
5 – management of biochemical recurrence after RT for localized ca prostate.
6 – management of oligometastatic prostate cancer.”
